Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12631734 | 0.84 | — | — | |
| SCHEMBL13405774 | 0.77 | — | — | |
| SCHEMBL9638686 | 0.64 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL8143101 | 0.62 | — | — | |
| SCHEMBL3533245 | 0.60 | ALDH1A1 (0.30) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15431588 | 0.56 | — | — | |
| SCHEMBL10959059 | 0.56 | — | — | |
| SCHEMBL5537467 | 0.54 | — | — | |
| SCHEMBL8213378 | 0.44 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL8099138 | 0.42 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4374248-A | ANTIHISTAMINES, ANTIULCER | BRISTOL-MYERS COMPANY (US) | 1983-02-15 | — | — | US | claimed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| EP-4313938-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | Modernatx, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117377653-A | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | 摩登纳特斯有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-05 | — | — | US | disclosed |
| WO-2022204288-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204288-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-4031527-A1 | HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-0112704-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-07-04 | — | — | EP | disclosed |
| EP-0112142-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-06-27 | — | — | EP | disclosed |
| EP-0111685-A1 | Benzazoles as histamine H2 receptor antagonists | Ikeda Mohando Co., Ltd. (JP) | 1984-06-27 | — | — | EP | disclosed |
| WO-1984000544-A1 | BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INT OVERSEAS (US) | 1984-02-16 | — | — | WO | disclosed |
| EP-0099121-A2 | Pharmaceutical compositions | Bristol-Myers Company (US) | 1984-01-25 | — | — | EP | disclosed |
| US-4394508-A | ANTIULCER AND ANTISECRETORY AGENTS; HISTAMINE ANTAGONIST | BRISTOL-MYERS COMPANY (US) | 1983-07-19 | — | — | US | disclosed |
| US-4380639-A | ANTIULCER AND ANTISECRETORY AGENTS | BRISTOL-MYERS COMPANY (US) | 1983-04-19 | — | — | US | disclosed |
| US-4380638-A | ANTIULCER AND ANTISECRETORY AGENTS; DERIVATIVES OF 3-AMINO-4-HET-A | BRISTOL-MYERS COMPANY (US) | 1983-04-19 | — | — | US | disclosed |
| US-4374248-A | ANTIHISTAMINES, ANTIULCER | BRISTOL-MYERS COMPANY (US) | 1983-02-15 | — | — | US | disclosed |
| EP-0065823-A1 | Heterocyclic guanidines as histamine H-2 antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PEBP1, PLTP | ALDH1A1 4749/4885CYP1A2 4879/4885CYP2C19 4863/4885 |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | ALDH1A1 4727/4885CYP1A2 4873/4885CYP2C19 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.